Vaxcyte Reports Second Quarter 2023 Financial Results and

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...

Related Keywords

Jennifer Zibuda ,Janet Graesser ,Michaele Kamarck ,Advisory Committee On Immunization Practices ,University Of Maryland ,Sutro Biopharma Inc ,Research Development Rd Expenses ,Exchange Commission ,Vaxcyte Inc ,Company Phase ,National Institutes Of Health ,Groupa Strep ,Drug Administration ,Adult Program ,Nasdaq ,Corporate Communications ,Second Stage ,Dosing First New Participants ,Topline Data ,Primary Immunization Series Expected ,Invasive Pneumococcal Disease ,Topline Phase ,Investigational New Drug ,Application Clearance Expected ,Fourth Quarter ,Cash Equivalents ,Including Net Proceeds ,April Public ,Advisory Committee ,Immunization Practices ,Grant Pickering ,Chief Executive Officer ,Second Quarter ,Recent Highlights ,Positive Data ,Full Six Month Safety Data ,Adult Phase ,Final Stage ,Dosed First New Participants ,Data Safety Monitoring Board ,Follow On Financing ,Novel Shigellao Polysaccharide ,Confers Protection ,Multiple Shigella Serotypes ,National Institutes ,Biologics License Application ,Breakthrough Therapy ,Sutro Biopharma ,Private Securities Litigation Reform Act ,Quarterly Report ,Vice President ,Investor Relations ,Senior Director ,Months Ended June ,Nasdaq Pcvx ,Maxcyte ,Nc ,Biotech ,Vaccines ,Healthcare ,